Telmisartan in the treatment of Cohen-Rosenthal diabetic hypertensive rats: The benefit of PPAR-γ agonism

Clinical and Experimental Hypertension

Volumn 29, Issue 6, 2007, Pages 419-426

  Younis, Firas ^a   Kariv, Naam ^a   Nachman, Rachel ^a   Zangen, Sara ^b   Rosenthal, Talma ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CRDH rats; Diabetes; Hypertension; PPAR agonist; Telmisartan

Indexed keywords

GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; COHEN ROSENTHAL DIABETIC HYPERTENSIVE RAT; COMORBIDITY; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN RESISTANCE; MALE; NONHUMAN; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; PPAR GAMMA; RATS; RATS, INBRED SHR;

EID: 34548299669     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960701578444     Document Type: Article

References (20)

1. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006;119(Suppl. 1):S3-S9.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
3. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.
4. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83.
5. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006;119(Suppl. 1):S24-S30.
6. Cohen AM, Rosenmann E, Rosenthal T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. Am J Hypertens. 1993;6:989-995.
7. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property. Med Hypotheses 2005;64:476-478.
8. Doggrell SA. Telmisartan - killing two birds with one stone. Expert Opin Pharmacother. 2004;5:2397-2400.
9. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004;27:1015.
10. Michel MC, Bohner H, Koster J. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Safety 2004;27:335-344.
11. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005;28:498.
12. Rodgers PT, Fuke DC. New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy 2006;26:13S-31S.
13. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004;43:993-1002.
14. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005; 42 (Suppl. 1):S9-S16.
15. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004;576:492-497.
16. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
17. Farley S. Metabolic syndrome: Two for the price of one. Nature Reviews Drug Discovery 2004;3:475.
18. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001;8:884-890.
19. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46:137-143.
20. Israeli ZH. Clinical pharmacokinetics of angiotension II (AT1) receptor blockers in hypertension. J Human Hypertens. 2000;14(Suppl 1).